Dopamine Agonists: all 968 studies that test it
Page 6 of 10. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.
- Social Decision Making in Parkinson's DiseaseCompletedNCT04249544Phase 1
- Changes in Glutamatergic Neurotransmission of Severe TBI PatientsSuspendedNCT04244058Early Phase 1
- An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy SubjectsCompletedNCT04241393Phase 1
- An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.TerminatedNCT04183634Phase 1
- Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation StudyCompletedNCT04162522Phase 3
- Pramipexole and Morphine for Renal ColicCompletedNCT04160520Phase 1/2
- Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain PlasticityWithdrawnNCT04082715Phase 2
- Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EESCompletedNCT04052776Phase 1
- Satisfaction of Patients With the Chosen Method of Inhibition of LactationStatus unknownNCT04038749Not applicable
- Effects of 5HTP and LDOPA on CNS Excitability After SCISuspendedNCT04000919Phase 2/3
- the Efficacy and Safety of Agomelatine in the Patients With Parkinson's DiseaseStatus unknownNCT03977441Phase 4
- Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral SclerosisCompletedNCT03929068Phase 1
- Cabergoline for the Treatment of Chronic Pain Due to EndometriosisCompletedNCT03928288Phase 2
- Oxytocin and Dopamine's Effect on Vicarious OptimismCompletedNCT03891095Not applicable
- Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)CompletedNCT03887884Phase 1
- Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-upStatus unknownNCT03883204Phase 4
- DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using AripiprazoleStatus unknownNCT03881449Phase 4
- A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy SubjectsCompletedNCT03874832Phase 1
- Safety and Efficacy of Brexpiprazole in the Treatment of SchizophreniaCompletedNCT03874494Phase 3
- A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I DisorderCompletedNCT03854409Phase 1
- Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia PatientsCompletedNCT03839251Phase 4
- Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis PatientsTerminatedNCT03817554Phase 4
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknownNCT03790085Early Phase 1
- WD-1603 PK Study in Healthy VolunteersCompletedNCT03761004Phase 1
- Pharmacological Modulation of Belief SalienceCompletedNCT03754062Phase 1
- The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese SubjectsCompletedNCT03734354Phase 1
- The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy SubjectsCompletedNCT03734302Phase 1
- Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HDTerminatedNCT03708237Phase 2
- Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French HospitalsCompletedNCT03693872Not applicable
- Pramipexole and Emotional ProcessingCompletedNCT03681509Not applicable
- A Study in Patients With Major Depressive DisorderActive, not recruitingNCT03642964Phase 2
- A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationCompletedNCT03636204Phase 1
- Treating Severe Brain-injured Patients With ApomorphineStatus unknownNCT03623828Phase 2
- Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained InfertilityStatus unknownNCT03549741Phase 2/3
- Dopamine Action on Metabolism in Relation to GenotypeCompletedNCT03525002Phase 2
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)CompletedNCT03510325Phase 3
- Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's SyndromeCompletedNCT03487783Phase 3
- Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic DisorderCompletedNCT03487770Phase 3
- The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive DisorderTerminatedNCT03487198Phase 3
- Substance Misuse To Psychosis for StimulantsCompletedNCT03485417Phase 2/3
- Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome PreventionCompletedNCT03473613Phase 3
- Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With ProlactinomaStatus unknownNCT03457389Not applicable
- Carbidopa-Levodopa in Dry AMD With Geographic AtrophyTerminatedNCT03451500Phase 2
- a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by AntipsychoticsCompletedNCT03430596Early Phase 1
- Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 DiabetesWithdrawnNCT03396484Phase 2
- Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DMEWithdrawnNCT03384524Phase 1/2
- MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical AntipsychoticsCompletedNCT03376763Phase 4
- A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient EnvironmentCompletedNCT03374917Phase 1
- Exceptional Experiences (EE), Salience & Dopaminergic NeurotransmissionCompletedNCT03333369Early Phase 1
- Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM PatientsStatus unknownNCT03313661Phase 3
- Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System DisordersCompletedNCT03292848Phase 1
- Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World StudyCompletedNCT03289026Phase 4
- Aripiprazole IM Depot for Chinese Patients With SchizophreniaCompletedNCT03287505Phase 1
- PK Study of Aripiprazole IM Depot for Chinese Patients With SchizophreniaCompletedNCT03285503Phase 1
- Cabergoline in Nonfunctioning Pituitary AdenomasCompletedNCT03271918Phase 3
- Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel ApproachCompletedNCT03266965Phase 1
- Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-ProtocolStatus unknownNCT03263299Phase 4
- Effects of Dopaminergic Therapy in Patients With Alzheimer's DiseaseCompletedNCT03250741Phase 2
- Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man SyndromeCompletedNCT03235037Not applicable
- Measuring Parkinson's Disease ProgressionCompletedNCT03205956Phase 1
- Aripiprazole IM Depot in the Acute Treatment of Adults With SchizophreniaCompletedNCT03172871Phase 3
- Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With SchizophreniaCompletedNCT03150771Phase 1
- A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward PathwayStatus unknownNCT03148509Phase 4
- Pharmacokinetic of Levodopa Study in Healthy MalesCompletedNCT03140956Phase 1
- A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult SubjectsCompletedNCT03121664Phase 1
- Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's DiseaseStatus unknownNCT03119636Phase 1/2
- Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's DiseaseCompletedNCT03111485Phase 4
- Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable SensorsStatus unknownNCT03098368Phase 4
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgCompletedNCT03097211Phase 1
- Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-upStatus unknownNCT03090503Phase 4
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseCompletedNCT03033498Phase 1
- The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular PainCompletedNCT02969629Phase 4
- Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic ProfileCompletedNCT02949752Phase 4
- Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseCompletedNCT02940912Phase 4
- Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT InhibitorWithdrawnNCT02929485Phase 4
- The Optimal Treatment for Treatment-resistant SchizophreniaStatus unknownNCT02926976Not applicable
- Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)CompletedNCT02864004Phase 3
- Studying a Potential Protective Effect of L-Dopa on Retinitis PigmentosaStatus unknownNCT02837640Phase 2
- Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsCompletedNCT02834507Phase 2
- A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsCompletedNCT02812394Phase 1
- A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)CompletedNCT02807675Phase 1
- Non Motors Aspects in De Novo Parkinson's DiseaseStatus unknownNCT02786667Phase 3
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/BenserazideCompletedNCT02778594Phase 1
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/CarbidopaCompletedNCT02774564Phase 1
- Comparison of the Effectiveness of Brexpiprazole With That of RisperidoneWithdrawnNCT02758067Phase 3
- Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseCompletedNCT02728947Phase 1
- Irritation and Sensitization Potential of Repeat Applications of Rotigotine PatchCompletedNCT02727205Phase 1
- The Effect of Dopamine on Diabetic RetinopathyCompletedNCT02706977Phase 1
- Apomorphine in Parkinson's Disease Patients With Visual HallucinationsStatus unknownNCT02702076Phase 2
- Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in SchCompletedNCT02697045Phase 4
- Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).TerminatedNCT02688465Phase 4
- The Role of miR-30 Family Dysregulation in Response to Antipsychotic TreatmentStatus unknownNCT02650102Phase 1/2
- Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary SyndromeStatus unknownNCT02644304Phase 2
- Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's DiseaseCompletedNCT02641054Phase 2
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or RisperidoneCompletedNCT02634463Phase 1
- A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking AdultsCompletedNCT02633839Phase 1
- A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With AsthmaCompletedNCT02633007Phase 1
- Bromocriptine in the Treatment of Peripartum CardiomyopathyWithdrawnNCT02590601Phase 3
- Combination Treatment for Augmenting Language in Children With ASDCompletedNCT02574741Phase 2
- Pharmacokinetic Study in Healthy VolunteersCompletedNCT02554734Phase 1